BMS returned license of anticancer Taxol

Published: 2016-01-06 15:34:23

Updated: 2016-01-06 15:34:33

BMS Pharmaceutical Korea declared a separation from co-promotion of anticancer Taxol with Boryung Pharm, as well as Baraclude.

According to the industry concerned on the 4^th, BMS Pharmaceutical Korea returned the license of anticancer Taxol from Boryung Pharm and has sold the product on its own from the 1^st of January. The agreement was terminated on 31 Dec. 2015.

Hearing the news last Decemb...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.